Oxygen-delivery drug for diseases caused by low oxygen
Pricing expected any day (our estimate) · latest SEC filing Oct 29, 2026.
Pinch-zoom for details.
NuvOx Therapeutics is a clinical-stage drug developer. Its candidate, NanO2, is an intravenous emulsion that turns to gas at body temperature to carry more oxygen to tissues, for diseases where lack of oxygen plays a critical role.
Fiscal year
1st 9 months
Fiscal year
1st 9 months
Fiscal year
1st 9 months
Cash and equivalents on the latest balance sheet, actual and as adjusted for the offering, as shown in the filing.
| $ | FY2024 | FY2025 | YoY | 9M 2025 | 9M 2026 | Change |
|---|---|---|---|---|---|---|
| Revenue | 512K | 980K | +91.4% | 876K | 856K | −2.3% |
| Operating result | (4.82M) | (5.10M) | −5.9% | (3.85M) | (3.60M) | +6.5% |
| Net result | (6.64M) | (16.6M) | −150% | (13.6M) | (7.00M) | +48.3% |
| $ | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Revenue | 512K | 980K | +91.4% |
| Operating result | (4.82M) | (5.10M) | −5.9% |
| Net result | (6.64M) | (16.6M) | −150% |
| $ | 9M 2025 | 9M 2026 | Change |
|---|---|---|---|
| Revenue | 876K | 856K | −2.3% |
| Operating result | (3.85M) | (3.60M) | +6.5% |
| Net result | (13.6M) | (7.00M) | +48.3% |
Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.
In plain English, from the filing's risk factors.
The filing doesn't set out its strategy in a list we could read.
Source: NuvOx Therapeutics, Inc.'s Form S-1/A, filed with the SEC on Oct 29, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back